First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid Arthritis

Phase 1

Completed

• Conditions: Inflammation; Rheumatoid Arthritis
• Interventions: Drug: NNC0142-0002; Drug: placebo

• Registration Number: NCT00927927
• Lead Sponsor: Janssen Research & Development, LLC

Brief Summary

This trial is conducted in Europe. The aim of this clinical trial is to investigate the safety, tolerability, pharmacokinetic (the effect of the body on the investigated drug) and signs of clinical efficacy of increasing single doses or four repeated doses of NNC 0142-0002 in patients with rheumatoid arthritis.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-06
• Study First Submitted: 2009-06-24
• Study First Submitted QC: 2009-06-24
• Study First Posted: 2009-06-25
• Primary Completion: 2011-12
• Study Completion: 2011-12
• Results First Submitted: 2013-04-25
• Results First Submitted QC: 2013-10-08
• Results First Posted: 2013-10-21
• Status Verified: 2016-08
• Last Update Submitted: 2016-08-24
• Last Update Posted: 2016-10-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 65

Inclusion Criteria

• Active rheumatoid arthritis, characterized by a Disease Activity Score (DAS28) above 3.2, and a diagnosis of at least three months duration
• Aged between 18 and 75 years (both inclusive)
• Subjects on stable doses of methotrexate for at least 4 weeks prior to dosing
• Use of highly effective contraception during the trial (both males and females)

Read More

Exclusion Criteria

• A chronic inflammatory autoimmune or joint disease other than RA (rheumatoid arthritis)
• An active or latent tuberculosis
• Any investigational or experimental therapy within 4 weeks or 5 half-lives (whichever is longer) prior to the screening visit
• A known significant cardio-vascular disease
• Vaccination against live virus or bacteria within 4 weeks prior to randomization
• The use of concomitant medications that are prohibited in the trial (e.g., certain DMARDs (antirheumatic therapies that are disease modifying), biologics (here: biotechnologically produced antibodies), intra-articular corticoid-injections, etc.)
• A positive test result for human immunodeficiency virus (HIV) infection, hepatitis B and/or hepatitis C, or tuberculosis skin test
• Donation of greater than or equal to 400 ml of blood within 8 weeks prior to trial entry

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
SD 0.007 mg/kg	NNC0142-0002	Subjects were injected once with NNC0142-0002 at a dose of 0.007 mg/kg
SD Placebo	placebo	Subjects were injected once with placebo
SD 0.0002 mg/kg	NNC0142-0002	Subjects were injected once with NNC0142-0002 at a dose of 0.0002 mg/kg
SD 0.035 mg/kg	NNC0142-0002	Subjects were injected once with NNC0142-0002 at a dose of 0.035 mg/kg
MD 4.0 mg/kg	NNC0142-0002	Subjects were injected biweekly four times with NNC0142-0002 at a dose of 4.0 mg/kg
SD 0.175 mg/kg	NNC0142-0002	Subjects were injected once with NNC0142-0002 at a dose of 0.175 mg/kg
SD 0.0012 mg/kg	NNC0142-0002	Subjects were injected once with NNC0142-0002 at a dose of 0.0012 mg/kg
MD 0.02 mg/kg	NNC0142-0002	Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.02 mg/kg
SD 0.7 mg/kg	NNC0142-0002	Subjects were injected once with NNC0142-0002 at a dose of 0.7 mg/kg
SD 7.5 mg/kg	NNC0142-0002	Subjects were injected once with NNC0142-0002 at a dose of 7.5 mg/kg
MD 0.3 mg/kg	NNC0142-0002	Subjects were injected biweekly four times with NNC0142-0002 at a dose of 0.3 mg/kg
MD 1.6 mg/kg	NNC0142-0002	Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.6 mg/kg
SD 2.5 mg/kg	NNC0142-0002	Subjects were injected once with NNC0142-0002 at a dose of 2.5 mg/kg
MD 1.0 mg/kg	NNC0142-0002	Subjects were injected biweekly four times with NNC0142-0002 at a dose of 1.0 mg/kg
MD Placebo	placebo	Subjects were injected biweekly four times with placebo

Primary Outcome Measures

Name	Time	Method
Frequency of Adverse Events	Adverse events were collected for a mean (min; max) of 15.7 (6.4; 42.6) weeks for single-dose subjects, and 30.6 (12.7; 43.1) for multiple-dose subjects. Visits were scheduled until receptor occupancy was below the cut-off level for receptor positivity.	Adverse event: any untoward medical occurrence in a subject or clinical investigation subject administered a pharmaceutical product, and which does not necessarily have a causal relationship with this treatment. Serious AE: AE that at any dose level resulted in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalization, a persistent/significant disability/incapacity, a congenital anomaly or birth defect, or an important medical event that may jeopardize the subject and require medical or surgical intervention.

Secondary Outcome Measures

Name	Time	Method
Area Under the Concentration-time Curve (AUC)	Data were collected from 0 hours to at least Day 43 (SD cohorts) and Day 85 (MD cohorts), and until the receptor occupancy was confirmed below the cut-off level for receptor positivity.	Systemic exposure to NNC0142-0002.